Geron shares rose 11%. Stifel Nicolaus analysts started the biotech company with a buy rating on Thursday morning. Target $4.
Up 24 cents just on a upgrade. My almost 9,000 shares love it. My 4,000 covered shares do not, but that's ok. We still need news, by all the signs it should be good. BUT I've been doing this for 40 years, it still could be a pump and dump, a secondary offering is coming.
Good luck in this rigged casino,
No comments:
Post a Comment